Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue

A technology for ischemic diseases and cell therapy, which can be used in extracellular fluid diseases, blood diseases, cardiovascular system diseases, etc., and can solve the problems of unstable storage of cell therapeutic agents.

Inactive Publication Date: 2010-05-19
RNL BIO +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, existing methods have problems in that stem cells are used auxiliary, or storage of cell therapeutics containing stem cells is unstable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue
  • Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue
  • Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Isolation of pluripotent stem cells from adipose tissue

[0053] Adipose tissue was obtained by abdominal liposuction, washed with PBS and then microdissected. The dissected tissue was digested at 37° C. for 2 hours in DMEM medium supplemented with collagenase type 1 (1 mg / ml). The digested tissue was washed with PBS and then centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated, and the micelles remaining at the bottom were washed with PBS, and then centrifuged at 1000 rpm for 5 minutes. The resulting micelles were filtered through a 100 μm sieve to remove debris, followed by washing with PBS. The obtained cells were incubated in DMEM medium (10% FBS, 2 mM NAC, 0.2 mM ascorbic acid). After overnight, unattached cells were washed away with PBS, and cultured in keratinocyte-SFM medium (containing 2mM NAC, 0.2mM ascorbic acid, 0.09mM calcium, 5ng / ml rEGF, 50μg / ml BPE, 5μg / ml Insulin and 74ng / ml hydrocortisone) were cultured, and the medium wa...

Embodiment 2

[0054] Example 2: Immunological properties of pluripotent stem cells from adipose tissue

[0055] The adipose tissue-derived pluripotent stem cells obtained in Example 1 were washed with PBS and treated with casein. Treated cells were collected and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, then washed with a mixture of 2% FBS and PBS, and centrifuged at 1000 rpm for 5 minutes. Discard the supernatant, suspend the cells in PBS, and for each sample mix 1 x 10 5Cells are dispersed into cell plates. Antibody (R-phycoerythrin-conjugated mouse anti-human monoclonal antibody) was placed into each well and incubated on ice for 40 minutes. After incubation, the medium was centrifuged at 1000 rpm for 5 minutes. Remove supernatant and wash cells twice with PBS. After washing, the cells were fixed with 1% paraformaldehyde, and then the surface antigens of pluripotent stem cells were analyzed by flow cytometry (Table 1 and figure 2 ).

[0056] Table 1: F...

Embodiment 3

[0060] Example 3: Pluripotent stem cell sphere preparations from human adipose tissue

[0061] The human adipose tissue-derived pluripotent stem cells obtained in Example 1 were stored under conditions of saline solution, saline solution+sucrose, saline solution+sucrose+50% albumin, and PBS+sucrose, and then their sphere-forming ability was examined.

[0062] will be 5×10 4 ~1×10 5 The pluripotent stem cells from human adipose tissue obtained in Example 1 were inoculated into a solution containing 10 μM CORM-2, 5 ml antibiotic antifungal (100×), 1 μg / ml cortisol, 5 μg / ml insulin, 20ng / ml EGF, 40ng / ml FGF, B27 and β-mercaptoethanol in each well of a 6-well plate in serum-free MEBM medium. As a result, cells began to form spherical shapes 3 to 7 days after inoculation, as image 3 As shown, the cells proliferated to form spheres even 7-10 days after inoculation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb lesions, and thus is useful to treat ischemic diseases.

Description

technical field [0001] The present invention relates to a cell therapy composition for treating ischemic limb diseases, in particular to a cell therapy composition for treating ischemic diseases, which contains mesenchymal stem cells from adipose tissue and excipient agent. Background technique [0002] Ischemic limb disease includes peripheral circulatory disturbance due to intravascular thrombosis, embolism, intravascular inflammation, hypertension, hyperlipidemia, and arterial and venous occlusion due to diabetic syndrome; such as burns or frostbite Symptoms caused by vascular damage caused by external factors such as; and thromboangiitis obliterans (Buerger's disease) manifested as blood inflammation and thrombus in middle-aged men who are heavily addicted to smoking, typical examples of which are arteriosclerosis obliterans, vascular occlusion vasculitis and similar diseases. [0003] Current methods of treating the disease include preferentially treating diseases tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/34A01N63/00C12N5/06A61K45/00A61P25/02
CPCA61K31/10A61K31/198A61K47/02A61K47/26A61K38/38A61K45/06A61K9/10A61K9/0019A61K9/08A61K47/183A61K47/42A61K47/20A61K35/28A61P7/00A61P7/02A61P9/10A61P9/14A61P17/02A61P25/02A61K2300/00
Inventor 韩惠晶李恒永金孝恩
Owner RNL BIO
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More